Università degli Studi di Padova

Padua Research Archive - Institutional Repository

Clinical syndromes associated with Coenzyme Q10 deficiency.

Original Citation:

Availability:

This version is available at: 11577/3280032 since: 2020-05-07T09:47:03Z

Publisher:

Portland Press

Published version:

DOI: 10.1042/EBC20170107

Terms of use:

Open Access

This article is made available under terms and conditions applicable to Open Access Guidelines, as described at <http://www.unipd.it/download/file/fid/55401> (Italian only)

(Article begins on next page)

Clinical syndromes associated with Coenzyme Q10 deficiency

María Alcázar-Fabra¹, Eva Trevisson², Gloria Brea-Calvo¹

1 Centro Andaluz de Biología del Desarrollo and CIBERER, Instituto de Salud Carlos III, Universidad Pablo de Olavide-CSIC-JA, Sevilla 41013, Spain; 2 Clinical Genetics Unit, Department of Women's and Children's Health, University of Padova, Padova 35128, Italy

Address correspondence to:

Dr. Gloria Brea-Calvo

Centro Andaluz de Biología del Desarrollo

Universidad Pablo de Olavide

Carretera de Utrera km 1

41013 Sevilla,

Spain

Email: gbrecal@upo.es

Tel. +34 954977637

Abstract

Primary Coenzyme Q deficiencies represent a group of rare conditions caused by mutations in one of the genes required in its biosynthetic pathway at the enzymatic or regulatory level. The associated clinical manifestations are highly heterogeneous and mainly affect central and peripheral nervous system, kidney, skeletal muscle and heart. Genotype-phenotype correlations are difficult to establish, mainly because of the reduced number of patients and

the large variety of symptoms. In addition, mutations in the same *COQ* gene can cause different clinical pictures. Here we present an updated and comprehensive review of the clinical manifestations associated to each of the pathogenic variants causing primary CoQ deficiencies.

Abbreviation list

2,4-dHB, 2,4-dihydroxybenzoic acid; 3,4-dHB, 3,4-dihydroxybenzoate; 4-HB, 4-hydroxybenzoate; CNS, central nervous system; CoQ, Coenzyme Q; EEG, electroencephalography; ESRD, end-stage renal disease; ETFDH, electron transport flavoprotein dehydrogenase; HHB, hexaprenyl-hydroxybenzoate; ID, intellectual disability; LDL, low density lipoproteins; mETC, mitochondrial electron transport chain; MRI, magnetic resonance imaging; OXPHOS, oxidative phosphorylation; pABA, para-aminobenzoic acid; PNS, peripheral nervous system; ROS, reactive oxygen species; SNHL, sensorineural hearing loss; SRNS, steroid-resistant nephrotic syndrome; VA, vanillic acid.

Please, refer to table 3 for symptoms abbreviations.

Coenzyme Q structure and function

Coenzyme Q (CoQ) or ubiquinone is the only endogenously synthesized redox-active lipid that is found in virtually all endomembranes, plasma membrane and serum lipoproteins, being especially abundant in mitochondria. It is composed of a benzoquinone ring as a head group, and a polyisoprenoid chain, which inserts the molecule into the phospholipid bilayer and varies in length depending on the species (figure 1A). In humans, it has 10 isoprene units (CoQ₁₀), 6 in *Saccharomyces cerevisiae* (CoQ₆) and the main form found in mice has 9 units (CoQ₉), although low amounts of CoQ₁₀ can be also detected in their membranes.

Soon after the first description by Cain and Morton in 1955 (1), the main function of CoQ in the mitochondrial electron transport chain (mETC) was proposed by Crane and cols., who also demonstrated its redox properties (2). In the mETC CoQ is an essential mobile electron

transport component, shuttling electrons from complex I (NADH-ubiquinone oxidoreductase) or complex II (succinate-ubiquinone oxidoreductase) to complex III (succinate-cytochrome c oxidoreductase).

CoQ is permanently going through oxidation-reduction cycles. It can be found in a completely reduced form (CoQH₂ or ubiquinol), after receiving two electrons, or in a completely oxidized form (CoQ or ubiquinone). When, as in the mETC, this redox cycle occurs by a two-step transfer of one electron each, a semiquinone (or semi-ubiquinone, CoQ•⁻) intermediate is produced (figure 1B).

Computational prediction models have recently confirmed studies describing how, in the inner mitochondrial membrane, CoQ is mainly located either close to the membrane-water interface, with its relatively small head group being shadowed by the bigger polar heads of phospholipids, or stabilized in the middle of the bilayer. During the process of electron transfer, CoQ rapidly translocates from one side to the other of the inner membrane bilayer, with a rate that varies depending on the redox state of the molecule. This process enables the interaction with the reducing and oxidizing sites in the proteins of the mETC complexes, located close to the membrane surfaces (3).

After the discovery of its role in the mETC, new functions have emerged for CoQ, being the electron acceptor for different dehydrogenases. Among others, in mitochondria CoQ accepts electrons from:

- (i) dihydroorotate dehydrogenase, a key enzyme for pyrimidine biosynthesis (4) ,
- (ii) mitochondrial glycerol-3-phosphate dehydrogenase (5), a tissue-specific component of mitochondria connecting glycolysis, oxidative phosphorylation and fatty acid metabolism (6),
- (iii) electron transport flavoprotein dehydrogenase (ETF_{FDH}), a key enzyme involved in the fatty acid β-oxidation and branched-chain amino acid oxidation pathways (7),

- (iv) proline dehydrogenase 1, an enzyme required for proline and arginine metabolism (8),
- (v) probably, from hydroxyproline dehydrogenase (or proline dehydrogenase 2), involved in the glyoxylate metabolism (9)
- (vi) sulphide-quinone oxidoreductase (10) during sulphide detoxification, a gas modulator of relevant cellular processes but toxic when in excess (11).

Reduced CoQ (CoQH₂) generated by all these processes is efficiently reoxidised by complex III in the mETC (figure 1C).

The ability to sustain continuous oxidation/reduction cycles makes CoQ not only a great electron carrier for different cellular processes, but also a potent membrane antioxidant, which protects lipids, proteins and nucleic acids from harmful oxidative damage (12,13). In membranes, CoQH₂ has been shown to prevent both initiation and propagation of lipid peroxidation (14,15) and, indirectly, to regenerate other antioxidants, such as α -tocopherol and ascorbate (16). The high efficiency of CoQ against oxidative stress may be related to its ubiquitous distribution, its localization in the core of membranes and the availability of diverse dehydrogenases, able to efficiently regenerate the molecule.

CoQ biosynthesis and regulation in eukaryotes/human

Levels of CoQ are quite stable in cells but its concentration varies among different tissues and organs, depending on dietary conditions and age (17–20). Although CoQ is mainly endogenously synthesized in mitochondria and then distributed to other cell membranes (21), cells can incorporate a certain amount from dietary sources. CoQ is synthesized by a set of nuclear-encoded COQ proteins, through a pathway that is not completely understood. Most of the work on CoQ biosynthesis has been done in *Saccharomyces cerevisiae*, and at least 13 yeast genes (*coq1* – *coq11*, *Yah1*, *Arh1*) have been identified as players of this process.

Information about the human pathway is very scarce, but orthologues of almost all of these genes have been already identified (see Dr. Clark review in this same number).

4-Hydroxybenzoate (4-HB), precursor of the benzoquinone ring, is synthesized from tyrosine, phenylalanine, or also para-aminobenzoic acid (pABA) in yeast, through a poorly characterized set of reactions (22–24). The isoprenoid tail comes from the mevalonate pathway, which is shared with cholesterol, among other molecules, and takes place in extra-mitochondrial membranes. This side chain is assembled by Coq1p (PDSS1 and PDSS2, acting as a heterotetramer, are the human orthologues), which also determines its length. Coq2p (human orthologue COQ2) condensates head and tail and the resulting molecule undergoes subsequent modifications of the ring moiety: C5-hydroxylation (yeast Coq6p, human COQ6) (25), O-methylations (yeast Coq3p, human COQ3) (26,27), C1-hydroxylation and C1-decarboxylation (unidentified), C2-methylation (yeast Coq5p, human COQ5) (28,29), and C6-hydroxylation (yeast Coq7p, human COQ7) (30), but also C4-deamination (Coq6p), in the case of yeast using pABA as precursor (24). Yah1 and Arh1 (human orthologues, FDXR and FDX2), mitochondrial ferredoxin and ferredoxin reductase, have been shown to transfer electrons to Coq6p (31). Mammalian pathway is still incompletely defined and significant efforts are required in order to determine whether it coincides with the yeast one (figure 2).

Other Coq proteins are thought to have regulatory functions. Coq8p (two human orthologues: COQ8A (or ADCK3/CABC1) and COQ8B (or ADCK4)), displays features of an atypical kinase that possibly phosphorylates Coq3p, Coq5p and Coq7p in yeast (32–34). However, COQ8A/ADCK3 has recently been shown to have a more clear ATPase activity (35) whose role in CoQ biosynthesis still needs to be further studied. Coq4p (human orthologue COQ4) function has not been elucidated yet, but it seems to be required for the formation and maintenance of the CoQ biosynthetic complex (36). Coq9p (human orthologue COQ9) is a lipid-binding protein stabilizing Coq7p (37,38). Coq10p (human orthologues COQ10A and COQ10B) probably

controls CoQ correct localization within the mitochondrial membranes (39). Coq11p is thought to be essential for CoQ synthesis in yeast, but lacks a clear human orthologue (40). Additionally, three other genes of the ADCK family (human *ADCK1*, *ADCK2* and *ADCK5*) have been proposed to participate in the biosynthetic process, but there is no experimental evidence for this (34,41).

It is widely accepted that yeast Coq3p-Coq9p proteins are organized in a multiprotein complex, possibly containing some intermediates of the biosynthesis and CoQ itself (40,42,43). The complex would probably optimize the orientation of the substrates and active sites of the enzymes as well as their functional coordination (36,44–47) (figure 2). Evidence supporting the existence of a conserved complex also in mammals has been recently reported by different groups through diverse approaches (23,29,35,38,48–52). However, functional organization and regulation of mammalian biosynthetic complex is still elusive and could be different from the yeast one.

Little is known about CoQ biosynthesis regulation, which may occur at the transcriptional, post-transcriptional and post-translational level, or even during the assembly of the putative multisubunit complex. Transcriptionally, several factors have emerged as possible candidates (53–55). However, a deep study of promoters and regulation sequences of the *COQ* genes is lacking currently. At the post-transcriptional level, several RNA binding proteins that modulate the stability of COQ transcripts have also been identified (56,57). At the post-translational level, processing by proteases, phosphorylation and dephosphorylation have been suggested to have a role in the regulation of some COQ proteins' activity, but only a very fragmented piece of information is currently available (33,34,58,59).

Clinical manifestations of CoQ deficiencies.

CoQ deficiencies have been associated with a wide range of clinical manifestations. Patients with CoQ deficiency have reduced levels of CoQ in tissues, which can be caused either by

mutations in the genes participating in CoQ biosynthesis, the so-called primary CoQ deficiencies, or by defects not directly linked CoQ biosynthesis, the secondary CoQ deficiencies.

Primary deficiencies.

Primary CoQ deficiencies are very rare conditions, usually associated with highly variable multisystemic manifestations (figure 3), and genetically caused by autosomal recessive mutations. Approximately 200 patients from 130 families have been described in the literature so far (Supplementary Table 1).

It has been estimated a worldwide total of 123,789 individuals (1 in 50,000) affected by primary CoQ deficiencies, being only 1,665 (less than 1 in 3,000,000) due to known pathogenic variants, taking into account the frequency of the different known or predicted pathogenic variants in given populations (60).

To date, ten genes encoding CoQ biosynthetic proteins have been shown to have pathogenic variants causing human CoQ deficiency: *PDSS1*, *PDSS2*, *COQ2*, *COQ4*, *COQ5*, *COQ6*, *COQ7*, *COQ8A*, *COQ8B* and *COQ9* (Table 1, supplementary table 1). They affect multiple organ systems in a highly variable way, including central nervous system (CNS) (encephalopathy, seizures, cerebellar ataxia, epilepsy or intellectual disability (ID)), peripheral nervous system (PNS), kidney (steroid-resistant nephrotic syndrome (SRNS)), skeletal muscle (myopathy), heart (hypertrophic cardiomyopathy) and sensory system (sensorineural hearing loss (SNHL), retinopathy or optic atrophy) (Table 2). While mutations in some *COQ* genes can affect different organs (e.g. *COQ2*, *COQ4*), pathogenic variants of other *COQ* genes show a more specific phenotype (e.g. *COQ8A*, *COQ8B*). Even more, mutations in the same *COQ* gene can cause very variable clinical phenotypes with different age of onset. The age of onset may generally range from birth to early childhood (*PDSS1*, *PDSS2*, *COQ2*, *COQ4*, *COQ5*, *COQ6*,

COQ7, *COQ9*), or from childhood to adolescence (*COQ8A*, *COQ8B*), but there are also some adult-onset cases (*COQ2* (61); *COQ8A* (62,63); *COQ8B* (64)).

CNS manifestations:

Central nervous system is often affected in these patients, showing a wide range of clinical manifestations, including encephalopathy, hypotonia, seizures, dystonia, cerebellar ataxia, epilepsy, stroke-like episodes, spasticity or ID. These symptoms may be present in patients with mutations in one of the reported COQ genes, but they are less prominent in patients with pathogenic variants of *COQ6* and *COQ8B*, in whom the more frequent phenotype is renal involvement. *COQ2* patients manifested early-onset nephrotic syndrome (17/22) which in some cases may be accompanied by encephalopathy and seizures (7/22) (65–76). *COQ4* patients generally show a severe CNS involvement, with encephalopathy and seizures (9/14), hypotonia (10/14) and cerebellar hypoplasia (6/14); and often a fatal outcome with death in the first days (6/14) or months (5/14) of life (77–81). The hallmark phenotype in *COQ8A* patients is slow progressive cerebellar atrophy and ataxia (43/45), associated with ID (19/45), epileptic seizures (18/45), tremor (18/45), dysarthria (16/45), saccadic eye movements (10/45), dystonia (9/45) or spasticity (8/45), among others (62,63,82–93). The only *COQ5* family described shows a phenotype similar to *COQ8A* patients (94). Some *COQ8A* patients (6/45) (62,84,85,87) and one *COQ2* patient (1/19) (66) suffered one stroke-like episode, that contributed significantly to deterioration of the neurological status and may explain the heterogeneity of the functional outcome among affected siblings (84). Some *COQ2* variants have also been predicted to increase susceptibility to adult-onset multisystem atrophy (MSA), but this issue is still under debate (61,95).

Very few patients with mutations in *PDSS1* (70,96), *PDSS2* (71,97–100), *COQ5* (94), *COQ7* (101,102) and *COQ9* (103–106) have been identified to define a specific phenotype, but they presented encephalopathy (*PDSS1*, *COQ9*), Leigh-like syndrome (*PDSS2*, *COQ9*), ataxia (*PDSS2*,

COQ5), ID (*PDSS1*, *PDSS2*, *COQ5*, *COQ7*), seizures (*PDSS2*, *COQ5*, *COQ9*) or spasticity (*PDSS2*, *COQ5*, *COQ7*).

Peripheral nervous system and sensory organs manifestations:

Peripheral neuropathy has been described in 2 siblings with *PDSS1* mutations, associated with optic atrophy and early-onset SNHL (70). Also, the 2 *COQ7* patients described showed peripheral polyneuropathy, again with SNHL and one of them with visual dysfunction (101,102). SNHL is very frequent, especially in *COQ6* patients (16/26) (69,71,107–109), associated with SRNS in all cases, and with optic atrophy (1/18) (109). One *COQ8A* patient (1/45) also showed early-onset bilateral SNHL (82–84), as well as patients with *PDSS2* mutations (4/7), who manifested retinitis pigmentosa (2/7) and optic atrophy (1/7), too (98,100). One patient with *COQ4* mutations (1/14) manifested bilateral hearing loss as well (77). Visual impairment was also a symptom in some patients with optic atrophy (*PDSS1* (70), *PDSS2* (98,100), *COQ2* (66), *COQ6* (109)), retinopathy (*COQ2* (74), retinitis pigmentosa (*PDSS2* (100), *COQ2* (61), *COQ8B* (110)) and cataracts (*PDSS2* (98), *COQ8A* (62)).

Renal manifestations:

SRNS is frequent in primary CoQ deficiency patients, specifically in patients with pathogenic variants of *COQ2*, *COQ6* and *COQ8B*. It generally starts as proteinuria and if untreated evolves to end-stage renal disease (ESRD) within childhood (71).

COQ2 patients displayed early-onset nephrotic syndrome (15/22) (65–68,70,71,73,76), isolated (9/22) or with encephalopathy and seizures (6/22), but there was also one family with onset in adolescence, slow progression of the renal disease and mild neurological symptoms (69). The hallmark of *COQ6* pathogenic variants is childhood-onset SNRS (23/26) associated with SNHL (16/26) (69,71,107–109,111). *COQ8B* patients mainly presented with an adolescence-onset SRNS due to focal segmental glomerulosclerosis, associated with edema (15/74) and

hypertension (10/74), which generally progressed to ESRD (50,64,110,112–116). Onset of SRNS may be before 10 years of age (29/74).

Patients with *PDSS1* (1/3) (96) and *PDSS2* (7/7) (71,97–100) mutations also showed SRNS. One *COQ9* (1/6) (104) and one *COQ2* (1/22) (75) patient displayed a tubulopathy.

Muscle manifestations:

Isolated myopathy has not been found in individuals with molecularly confirmed primary CoQ deficiency. The majority of the patients with a predominantly muscular phenotype have been associated with secondary CoQ deficiency. Myopathy has been described in some patients with a multisystemic phenotype (*COQ4* (1/14) (81), *COQ8A* (1/45) (91)). Other muscular manifestations include exercise intolerance (*COQ8A* (8/45) (82,84–86)), muscle weakness (*COQ2* (1/22) (66), *COQ6* (2/26) (109), *COQ7* (2/2) (101,102), *COQ8A* (7/45) (62,85,87,92), *COQ8B* (1/74) (113)) and muscle fatigue (*COQ8A* (2/45) (62,90) and *COQ8B* (1/74) (110)). Some muscle biopsies have shown lipid accumulation in muscle (*COQ4* (1/14) (81), *COQ8A* (3/45) (62,85), *COQ2* (1/22) (72)).

Cardiac manifestations:

The most frequent heart manifestation is hypertrophic cardiomyopathy, often present in *COQ4* patients with a prenatal onset (7/14) (77–79), whereas *COQ2* (3/22) (65,72,75), *COQ8B* (2/74) (64,112,113), *COQ7* (1/2) (101) and *COQ9* patients (1/6) (104) show a neonatal onset. Other less frequently reported cardiac manifestations are valvulopathies (*PDSS1* (2/3) (70)), heart hypoplasia (*COQ4* (1/14) (78)), septal defects (*COQ4* (1/14) (81), *COQ8B* (2/74) (110,116)), heart failure (*COQ4* (2/14) (78,79) and *COQ8B* (1/74) (110)), bradycardia (*COQ4* (4/14) (77–79), *COQ9* (2/6) (105,106), or pericardial effusion (*COQ8B* (1/74) (64,112)). However, it is questionable whether some manifestations such as heart failure, bradycardia or pericardial effusion are primary events or are secondary manifestations of some other general

phenomena.

Other manifestations:

Less frequent clinical findings include dysmorphic features (81,107), metabolic pathologies (diabetes mellitus (70,75), obesity (70) and hypercholesterolemia (69,113) -although the latest is often observed during SRNS, independently of its aetiology-), thyroid disease (goiter (50,112), hypothyroidism (64)), lung involvement (respiratory distress -very frequent in COQ4 patients (9/14) (75,78,79,101,105)-, apnea (74,77–79,105) or respiratory failure (66,74,75,77,78)), circulatory problems (cyanosis (78,105), hypertension, livedo reticularis (70)), liver abnormalities (hepatic insufficiency (70,72), cholestatic liver (75)), among others.

Biochemical findings:

Primary CoQ deficiency patients, particularly those with neonatal onset, can show higher levels of lactate in plasma or serum. CoQ levels in skeletal muscle biopsies or fibroblasts may be reduced (117), as well as the enzymatic activities of complex I+III and/or II+III (118).

Pathogenesis

The pathogenesis of CoQ deficiency is complex and not completely understood. The bioenergetic defect and the increased reactive oxygen species (ROS) production may have a crucial role. However the wide spectrum of CoQ functions, the unclear roles of some COQ gene products and the considerable phenotypic variability, suggest that other mechanisms contribute to the pathogenesis of the disease. In cultured cells it has been found that, while severe CoQ deficiencies lead to great defects in energy production with no major increase in oxidative stress, mild CoQ defects cause a significant increase in ROS production without affecting ATP production, but yielding increased cell death levels (119). In addition, as expected, CoQ deficiency impairs *de novo* pyrimidine synthesis, further contributing to disease pathogenesis (120). CoQ deficiency cells also show increased mitophagy, being proposed as a

protective mechanism in disease pathogenesis (121), although other authors defined it as detrimental (122). Recently, sulfide oxidation pathway impairment has been proposed as an additional pathomechanism in primary CoQ deficiency, as different *in vivo* and *in vitro* models of the disease show a tissue-specific defect in the metabolism of H₂S, leading to the accumulation of this molecule, that may alter protein S-sulfhydrylation, inducing changes such as vasorelaxation, inflammation and ROS production (123). Finally, CoQ deficiency has been linked to development of insulin resistance in human and mouse adipocytes, as a result of increased ROS production via complex II (124).

Genotype-phenotype correlation

Due to the small number of patients harbouring mutations in COQ genes and the wide range of clinical manifestations, it is arduous to define genotype-phenotype correlations. In fact, only a few families with pathogenic variants of *PDSS1*, *PDSS2*, *COQ5* or *COQ9* have been published, being unachievable to establish any correlation. In the case of *COQ9*, studies in two mouse models suggest that a key factor appears to be the different degree of impairment of formation of the CoQ complex (49). Even though only 2 patients with *COQ7* mutations have been described, there seems to be a correlation between the residual levels of CoQ (and levels of COQ7 protein) and the severity of the disease: fibroblasts from patient with the most severe phenotype show a drastic CoQ deficiency (101), while the patient with the milder phenotype has a 30% decrease in CoQ levels in skin fibroblasts (102). Interestingly, only fibroblasts with a severe deficiency benefit from 2,4-dihydroxybenzoic acid (2,4-dHB) supplementation, while CoQ biosynthesis was inhibited in those with the milder defect treated with 2,4-dHB.

COQ8A and *COQ8B* have the highest number of families with pathogenic variants reported (29 and 38), and in neither case there is any correlation between the mutations and the clinical phenotype (84,112). In the case of *COQ2* patients (18 families described), who show the widest clinical spectrum, it has been proposed that the severity of the disease correlates with the

enzymatic residual activity and hence CoQ levels, as shown by expressing mutant proteins in yeast (125). It is worth to mention that most of the *COQ6* patients were diagnosed during screening for SNRS, so there may be a reference bias in these cases (71,107,109). To date, no other clear correlations have been observed for *COQ4* patients.

Diagnosis

The diagnosis of primary CoQ deficiency is established with the identification of biallelic pathogenic variants in any of the genes coding for one of the proteins directly involved in CoQ biosynthesis. Genome or specific gene sequencing is performed when decreased levels of CoQ or reduced combined activities of complex I+III and II+III in mitochondria of skeletal muscle biopsies are detected in patients (126,127). It is important to note that biochemical analysis is not able to distinguish between primary and secondary CoQ deficiencies (127). Genetic identification of new pathogenic variants is usually followed by functional validation.

CoQ levels can also be measured on plasma samples, white blood cells or skin fibroblasts obtained after skin biopsy from patients (128). However, there are concerns about CoQ plasma measurements for diagnosis, since it seems to be influenced by the amount of plasma lipoproteins (carriers of CoQ in circulation) and the dietary intake. Muscle or fibroblasts represent the preferred diagnosis tissues, although sometimes fibroblasts do not show reduction while muscle does (129). It has been shown that white blood cells CoQ levels alone are not reliable to diagnose primary CoQ deficiency in the setting of nephrotic syndrome (76). *De novo* synthesis can also be measured by radioactive precursor incorporation in fibroblasts (130) which is especially useful to discriminate between primary and secondary deficiencies. Recently, urine CoQ measurement as non-invasive approach has been proposed (131).

Management

Considering the wide clinical spectrum of this condition, any individual with a diagnosis of primary CoQ deficiency should be assessed, in order to establish the severity of the disease.

Importantly, a genetic consultation is recommended for other family members and for recurrence risk of patient's parents. Based on the genetic defect identified in the patient, a specific follow-up should be programmed.

Being CNS manifestations very frequent, every patient with a diagnosis of CoQ deficiency should undergo periodical neurological examinations, even if normal at diagnosis. In fact, the age of onset of these symptoms is highly variable, ranging from the first hours or days of life (as in patients with *COQ4* mutations), up to the seventh decade of life (as in *COQ2* patients with the adult-onset multisystem atrophy-like phenotype). Evaluation should include an EEG analysis and a brain MRI. In addition, peripheral nervous system should be assessed for the possible presence of peripheral neuropathy in patients with *PDSS1* and *COQ7* mutations.

Patients with mutations in *PDSS1*, *PDSS2*, *COQ2*, *COQ6*, *COQ7*, *COQ8A* and *COQ8B* may have eye involvement due to optic atrophy, retinopathy, retinitis pigmentosa and even cataracts and should therefore be screened at diagnosis and during the follow-up. Audiometry is necessary in *COQ6* patients who almost invariably manifest SRNS, but should be performed also in patients with mutations in *PDSS1*, *COQ8A* and *COQ4* who may sometimes manifest this phenotype.

Individuals harbouring mutations in *COQ2*, *PDSS1*, *PDSS2*, *COQ6*, and *COQ8B* may manifest renal involvement with SRNS, whose onset may vary from early childhood to adolescence. Tubulopathy has been reported rarely. These patients thus need to undergo periodical renal function tests with urine analysis for proteinuria and nephrological evaluations for the risk of evolving to ESRD.

A cardiologist examination with echocardiogram should be performed in patients with *COQ4* mutations (who may present with a severe prenatal-onset cardiomyopathy) and should also be considered in individuals with mutations in *PDSS1* and *COQ8B* to exclude the presence of a valvulopathy or septal defects.

Treatment

Barriers for tissues CoQ delivery have been found due to its high molecular weight and poor aqueous solubility, but at high doses, dietary supplementation increases CoQ levels in all tissues, including heart and brain, especially with certain formulations (132,133). It also increases in circulating low density lipoproteins (LDL), where it functions as an efficient antioxidant together with α -tocopherol (134,135). CoQ supplementation at high doses has been demonstrated to be effective for treatment of both primary and secondary CoQ deficiencies (136). It is crucial to start the supplementation as soon as possible to get favorable outcomes and to limit irreversible damage in critical tissues such as the kidney or the CNS (126). Different doses of CoQ have been employed for the treatment of primary CoQ deficiencies, ranging from 5 mg/kg/day (98) to 30-50 mg/kg/day for both adults and children (137) but in mouse models of this condition even higher doses (up to 200 mg/kg/day) have been used (138). Except for *COQ8A* patients, most individuals with primary forms show a good response to CoQ treatment, which is usually evident after 10-20 days (137). Different formulations of CoQ are now available, both in the oxidized and the reduced forms, although most of the data available have been obtained in patients treated with ubiquinone.

Alternatively to CoQ₁₀ supplementation, some 4-HB analogues have been proposed as potential bypass molecules with higher bioavailability than CoQ. These water-soluble CoQ head precursors would bypass enzymatic steps disrupted by mutations in *COQ* genes, but their efficacy may differ depending on the stability of the CoQ biosynthetic complex. Some examples are vanillic acid (VA) and 3,4-dihydroxybenzoate (3,4-dHB), able to bypass *COQ6* mutations, or 2,4-dHB for *COQ7* defects (figure 2C and 2D). The effectivity of VA and 3,4-dHB in restoring CoQ biosynthesis has been demonstrated in *coq6* yeast mutant strains expressing pathogenic versions of human *COQ6* (111). Notably, VA also stimulates CoQ synthesis and

improves cell viability in *COQ9* patient fibroblasts (139). 2,4-dHB was able to increase CoQ levels and lifespan in *Coq7* (140) and *Coq9* defective mice (49), as well as to bypass the reaction in human fibroblasts with *COQ7* (101,102,139) and *COQ9* mutations (139). Remarkably, the effectivity of 2,4-dHB depends on the nature of the *COQ7* mutation and the residual activity of the protein (102). It has also been reported that treatment with high doses of 4-HB, thus increasing COQ2 substrate availability, restores CoQ synthesis in *COQ2* deficient cell lines, which also suggests that these enzyme variants retain some residual activity (141).

Early onset CoQ deficiencies can cause mortality in few days. We have observed that CoQ is efficiently incorporated in different tissues by breastfeeding and placenta in mice (unpublished data). We propose treatment of pregnant mothers of high-risk newborns (high probability of CoQ deficiency after genetic screening or due to family history) with CoQ supplementation, in order to reduce tissue damage during embryonic/fetal development and to increase the survival of newborns until they can be fed with supplements.

Secondary deficiencies

CoQ levels can also be reduced secondary to conditions not directly linked to CoQ biosynthesis, but related to oxidative phosphorylation (OXPHOS), other non-OXPHOS mitochondrial processes, or even to non-mitochondrial functions (142). Remarkably, secondary CoQ deficiencies are proved to be more common than primary deficiencies (142,143), probably because of the diversity of biological functions and metabolic pathways in which CoQ is involved in mitochondrial and non-mitochondrial membranes, highlining the importance of CoQ homeostasis in human health. However, there is a lack of consistency of CoQ deficiency presence among different patients, which could suggest different susceptibility to the development of secondary deficiencies among different individuals. Currently, there is not any general explanation for this, although genetic factors, such as certain polymorphisms, have been proposed to be involved (112,142–144). A comprehensive analysis of muscle and

fibroblasts samples from patients affected by a wide range of mitochondrial diseases, showed that secondary deficiencies were more frequent in depletion syndromes than in any other mitochondrial disease (142), supporting previous observations (145). The same study analysed CoQ levels in samples of patients affected by different OXPHOS diseases, but were unable to find any difference between them. Further studies on wider cohorts are needed in order to understand whether certain diseases are more prone to develop secondary deficiencies than others, as well as the underlying molecular mechanism. Nonetheless, it is clear that mitochondrial myopathies are frequently associated with CoQ secondary deficiencies (144). Besides its reduction in many mitochondrial OXPHOS disorders, other diseases may display secondary CoQ deficiency, including ataxia and oculomotor apraxia syndrome (MIM #208920), multiple acyl-CoA dehydrogenase deficiency (MIM #231680), cardiofaciocutaneous syndrome (MIM #115150), methylmalonic aciduria (# 251000), GLUT-1 deficiency syndrome (MIM #606777), mucopolysaccharidosys type III (MIM #605270) or multisystem atrophy (142,143,146). The mechanisms underlying CoQ secondary defects remain largely unknown, but several explanations have been proposed that are related to: (i) an increased rate of CoQ degradation due to oxidative damage caused by a non-functional respiratory chain; (ii) a decrease in CoQ through the interference with the signalling pathways involved in the process of biosynthesis; (iii) the reduction of the stability of the CoQ biosynthetic complex or (vi) a general deterioration of mitochondrial function (142,143).

In addition, CoQ seems to be reduced in the process of aging (147) and a secondary deficiency of CoQ may be a side effect of hypercholesterolemia treatment with statins, since both cholesterol and CoQ share part of their biosynthetic pathways (148,149).

Of course, particular symptoms of secondary CoQ deficiencies are highly dependent on the original pathology. Myopathies presented as muscular weakness, hypotonia, exercise intolerance or myoglobinuria are commonly reported as muscular manifestations in diseases

associated to secondary CoQ deficiencies. Neurological decline and ataxia are also often reported (143,150). It is possible that the primary disease symptoms are potentiated by the lack of CoQ (143). In fact, many of these patients partially improve their condition by CoQ supplementation, which supports the importance of an early diagnosis also in these cases (150). From the point of view of the molecular diagnosis, it is necessary to perform a genetic analysis to distinguish between primary and secondary deficiencies (126).

Concluding remarks

The deficiency in CoQ is a genetically and clinically heterogeneous syndrome. Primary deficiency diagnosis is a great challenge due to the number of genes involved, the poor knowledge of CoQ biosynthesis pathway and its regulation in humans, the small number of patients described and the great variety of associated symptoms. Moreover, secondary deficiencies can be consequences of many other mitochondrial dysfunctions adding a layer of complexity to the diagnosis. Observation of the clinical manifestations here described and /or the molecular identification of potentially pathological variants of *COQ* genes should be complemented by the biochemical determination of CoQ levels, biosynthesis rate if possible, and the combined enzymatic activities of complexes I+III and I+II in muscle or fibroblast. It is important to identify potential cases as early as possible because high-dose CoQ oral supplementation is a very effective treatment in most cases, blocking the progression of the disease.

Acknowledgements

Authors wish to thank the patients and their families for facilitating the research here reviewed. We thank Prof. Plácido Navas for the critical revision of the manuscript.

Declaration of interest

The authors report no conflicts of interest.

Funding information

MA-F is a predoctoral research fellow from the Spanish Ministry of Education, Culture and Sports (FPU14/04873). ET is supported by Grant number CPDA140508/14 from University of Padova.

Author contribution statement

MA-F exhaustively compiled the mutations and symptoms data from literature and elaborated the tables. MA-F and GB-C made the figures. MA-F, ET and GB-C wrote and edited the text and GB-C coordinated the work.

References

1. Cain JC, Morton R. Some minor constituents of liver oils. *Biochem J.* 1955;60(2):274–83.
2. Crane FL, Hatefi Y, Lester R, Widmer C. Isolation of a quinone from beed heart mitochondria. *Biochim Biophys Acta.* 1957;25(1):220–1.
3. Kaurola P, Sharma V, Vonk A, Vattulainen I, Róg T. Distribution and dynamics of quinones in the lipid bilayer mimicking the inner membrane of mitochondria. *Biochim Biophys Acta - Biomembr.* 2016;1858(9):2116–22.
4. Evans DR, Guy HI. Mammalian pyrimidine biosynthesis: fresh insights into an ancient pathway. *J Biol Chem.* 2004/04/21. 2004;279(32):33035–8.
5. Rauchová H, Battino M, Fato R, Lenaz G, Drahota Z. Coenzyme Q-pool function in glycerol-3-phosphate oxidation in hamster brown adipose tissue mitochondria. *J Bioenerg Biomembr.* 1992;24(2):235–41.
6. Mráček T, Drahota Z, Houštěk J. The function and the role of the mitochondrial glycerol-3-phosphate dehydrogenase in mammalian tissues. *Biochim Biophys Acta - Bioenerg.* 2013;1827(3):401–10.
7. Watmough NJ, Frerman FE. The electron transfer flavoprotein: ubiquinone oxidoreductases. *Biochim Biophys Acta.* 2010/10/13. 2010;1797(12):1910–6.
8. Blake RL, Hall JG, Russell ES. Mitochondrial Proline Dehydrogenase Deficiency in Hyperprolinemic PRO / Re Mice : Genetic and Enzymatic Analyses. *Biochem Genet.* 1976;14(9–10):739–57.
9. Summit CB, Johnson LC, Jönsson TJ, Paesonage D, Holmes RP, Lowther QT. Proline dehydrogenase 2 (PRODH2) is a hydroxyproline dehydrogenase (HYPDH) and molecular target for treating primary hyperoxaluria. *Biochem J.* 2015;466(2):273–81.
10. Hackfort BT, Mishra PK. Emerging role of hydrogen sulfide-microRNA cross-talk in cardiovascular diseases. *Am J Physiol Heart Circ Physiol.* 2016;310(7):H802–12.
11. Ziosi M, Di Meo I, Kleiner G, Gao X-H, Barca E, Sanchez-Quintero MJ, et al. Coenzyme Q

476 deficiency causes impairment of the sulfide oxidation pathway. *EMBO Mol Med.*
477 2017;9(1):96–111.

478 12. Forsmark-Andrée P, Dallner G, Ernster L. Endogenous ubiquinol prevents protein
479 modification accompanying lipid peroxidation in beef heart submitochondrial particles.
480 *Free Radic Biol Med.* 1995;19(6):749–57.

481 13. Godic A, Poljsak B, Adamic M, Dahmane R. The role of antioxidants in skin cancer
482 prevention and treatment. *Oxid Med Cell Longev.* 2014;2014:860479.

483 14. Maroz A, Anderson RF, Smith RAJ, Murphy MP. Reactivity of ubiquinone and ubiquinol
484 with superoxide and the hydroperoxyl radical: implications for in vivo antioxidant
485 activity. *Free Radic Biol Med.* 2009;46(1):105–9.

486 15. Bentinger M, Brismar K, Dallner G. The antioxidant role of coenzyme Q. *Mitochondrion.*
487 2007;7(Supplement):S41–50.

488 16. Mukai K. Free Radical Chemistry of Coenzyme Q. In: Kagan, V. E.; Guinn PJ, editor.
489 *Coenzyme Q Molecular Mechanisms in Health and Disease.* 1st Ed. Taylor & Francis
490 Group; 2001. p. 43–61.

491 17. Sohal RS, Forster MJ. Coenzyme Q, oxidative stress and aging. *Mitochondrion.*
492 2007;7(Supplement):S103–11.

493 18. Parrado C, López-Lluch G, Rodríguez-Bies E, Santa-Cruz S, Navas P, Ramsey J, et al.
494 Calorie restriction modifies ubiquinone and COQ transcripts levels in mouse tissues.
495 *Free Radic Biol Med.* 2011;50(12):1728–36.

496 19. Lopez-Lluch G, Rodríguez-Aguilera JC, Santos-Ocaña C, Navas P. Is Coenzyme Q a key
497 factor in aging? *Mech Ageing Dev.* 2010;131(4):225–35.

498 20. Varela-López A, Giampieri F, Battino M, Quiles JL. Coenzyme Q and its role in the
499 dietary therapy against aging. *Molecules.* 2016;21(3):373.

500 21. Fernandez-Ayala DJ, Brea-Calvo G, Lopez-Lluch G, Navas P. Coenzyme Q distribution in
501 HL-60 human cells depends on the endomembrane system. *Biochim Biophys Acta.*
502 2005;1713(2):129–37.

503 22. Payet L-A, Leroux M, Willison JC, Kihara A, Pelosi L, Pierrel F. Mechanistic Details of
504 Early Steps in Coenzyme Q Biosynthesis Pathway in Yeast. *Cell Chem Biol.* 2016 Oct
505 20;23(10):1241–50.

506 23. Stefely J, Kwiecien N, Freiburger E, Richards A, Jochem A, Rush M, et al. Mitochondrial
507 protein functions elucidated by multi-omic mass spectrometry profiling. *Nat Biotechnol.*
508 2016;34(11):1191–7.

509 24. Marbois B, Xie LX, Choi S, Hirano K, Hyman K, Clarke CF. para-aminobenzoic acid is a
510 precursor in coenzyme Q6 biosynthesis in *Saccharomyces cerevisiae*. *J Biol Chem.*
511 2010;285(36):27827–38.

512 25. Ozeir M, Mühlenhoff U, Weibert H, Lill R, Fontecave M, Pierrel F. Coenzyme Q
513 biosynthesis: Coq6 is required for the C5-hydroxylation reaction and substrate analogs
514 rescue Coq6 deficiency. *Chem Biol.* 2011;18(9):1134–42.

515 26. Jonassen T, Clarke CF. Isolation and functional expression of human COQ3, a gene
516 encoding a methyltransferase required for ubiquinone biosynthesis. *J Biol Chem.*
517 2000;275(17):12381–7.

- 518 27. Poon WW, Barkovich RJ, Hsu Y, Frankel A, Lee PT, Shepherd N, et al. Yeast and Rat Coq3
519 and Escherichia coli UbiG Polypeptides Catalyze Both O -Methyltransferase Steps in
520 Coenzyme Q Biosynthesis. J Biol Chem. 1999;274(31):21665–72.
- 521 28. Barkovich RJ, Shtanko A, Shepherd J a, Lee PT, Myles DC, Tzagoloff A, et al.
522 Characterization of the COQ5 Gene from Saccharomyces cerevisiae. Biochemistry.
523 1997;272(14):9182–8.
- 524 29. Nguyen TPT, Casarin A, Desbats MA, Doimo M, Trevisson E, Santos-Ocaña C, et al.
525 Molecular characterization of the human COQ5 C-methyltransferase in Coenzyme Q10
526 biosynthesis. Biochim Biophys Acta - Mol Cell Biol Lipids. 2014;1841(11):1628–38.
- 527 30. Marbois BN, Clarke CF. The COQ7 Gene Encodes a Protein in Saccharomyces cerevisiae
528 Necessary for Ubiquinone Biosynthesis. J Biol Chem. 1996;271(6):2995–3004.
- 529 31. Pierrel F, Hamelin O, Douki T, Kieffer-Jaquinod S, Mühlenhoff U, Ozeir M, et al.
530 Involvement of mitochondrial ferredoxin and para-aminobenzoic acid in yeast
531 coenzyme Q biosynthesis. Chem Biol. 2010;17(5):449–59.
- 532 32. Tauche A, Krause-Buchholz U, Rödel G. Ubiquinone biosynthesis in Saccharomyces
533 cerevisiae: The molecular organization of O-methylase Coq3p depends on
534 Abc1p/Coq8p. FEMS Yeast Res. 2008;8(8):1263–75.
- 535 33. Xie LX, Hsieh EJ, Watanabe S, Allan CM, Chen JY, Tran UC, et al. Expression of the
536 human atypical kinase ADCK3 rescues coenzyme Q biosynthesis and phosphorylation of
537 Coq polypeptides in yeast coq8 mutants. Biochim Biophys Acta. 2011;1811(5):348–60.
- 538 34. Stefely JA, Reidenbach AG, Ulbrich A, Oruganty K, Floyd BJ, Jochem A, et al.
539 Mitochondrial ADCK3 Employs an Atypical Protein Kinase-like Fold to Enable Coenzyme
540 Q Biosynthesis. Mol Cell. 2015;57(1):83–94.
- 541 35. Reidenbach AG, Kemmerer ZA, Aydin D, Jochem A, McDevitt MT, Hutchins PD, et al.
542 Conserved Lipid and Small-Molecule Modulation of COQ8 Reveals Regulation of the
543 Ancient Kinase-like UbiB Family. Cell Chem Biol. 2018;25(2):154–165.e11.
- 544 36. Marbois B, Gin P, Gulmezian M, Clarke CF. The yeast Coq4 polypeptide organizes a
545 mitochondrial protein complex essential for Coenzyme Q biosynthesis. Biochim Biophys
546 Acta. 2009;1791(1):69–75.
- 547 37. Hsieh EJ, Gin P, Gulmezian M, Tran UPC, Saiki R, Marbois BN, et al. Saccharomyces
548 cerevisiae Coq9 polypeptide is a subunit of the mitochondrial Coenzyme Q biosynthetic
549 complex. Arch Biochem Biophys. 2007;463(1):19–26.
- 550 38. Lohman DC, Forouhar F, Beebe ET, Stefely MS, Minogue CE, Ulbrich A, et al.
551 Mitochondrial COQ9 is a lipid-binding protein that associates with COQ7 to enable
552 Coenzyme Q biosynthesis. Proc Natl Acad Sci U S A. 2014;111(44):E4697-705.
- 553 39. Cui TZ, Kawamukai M. Coq10, a mitochondrial Coenzyme Q binding protein, is required
554 for proper respiration in Schizosaccharomyces pombe. FEBS J. 2009;276(3):748–59.
- 555 40. Allan CM, Awad AM, Johnson JS, Shirasaki DI, Wang C, Blaby-Haas CE, et al.
556 Identification of Coq11, a new coenzyme Q biosynthetic protein in the CoQ-synthome
557 in saccharomyces cerevisiae. J Biol Chem. 2015;290(12):7517–34.
- 558 41. Desbats MA, Lunardi G, Doimo M, Trevisson E, Salviati L. Genetic bases and clinical
559 manifestations of coenzyme Q10 (CoQ 10) deficiency. J Inherit Metab Dis. 2014 Aug;10.
- 560 42. Padilla S, Tran UC, Jiménez-Hidalgo M, López-Martín JM, Martín-Montalvo A, Clarke CF,

561 et al. Hydroxylation of demethoxy-Q6 constitutes a control point in yeast coenzyme Q6
562 biosynthesis. *Cell Mol Life Sci.* 2009;66(1):173–86.

563 43. He CH, Xie LX, Allan CM, Tran UC, Clarke CF. Coenzyme Q supplementation or over-
564 expression of the yeast Coq8 putative kinase stabilizes multi-subunit Coq polypeptide
565 complexes in yeast coq null mutants. *Biochim Biophys Acta.* 2014;1841(4):630–44.

566 44. Poon WW, Do TQ, Noelle Marbois B, Clarke CF. Sensitivity to treatment with
567 polyunsaturated fatty acids is a general characteristic of the ubiquinone-deficient yeast
568 coq mutants. *Mol Aspects Med.* 1997;18(Supplement 1):121–7.

569 45. Baba SW, Belogrudov GI, Lee JC, Lee PT, Strahan J, Shepherd JN, et al. Yeast Coq5 C-
570 methyltransferase is required for stability of other polypeptides involved in Coenzyme
571 Q biosynthesis. *J Biol Chem.* 2004;279(11):10052–9.

572 46. Gin P, Clarke CF. Genetic Evidence for a Multi-subunit Complex in Coenzyme Q
573 Biosynthesis in Yeast and the Role of the Coq1 Hexaprenyl Diphosphate Synthase. *J Biol*
574 *Chem.* 2005;280(4):2676–81.

575 47. Gonzalez-Mariscal I, Garcia-Teston E, Padilla S, Martin-Montalvo A, Pomares-Viciano T,
576 Vazquez-Fonseca L, et al. Regulation of coenzyme Q biosynthesis in yeast: a new
577 complex in the block. *IUBMB Life.* 2014;66(2):63–70.

578 48. Stefely JA, Licitra F, Laredj L, Reidenbach AG, Kemmerer ZA, Grangeray A, et al.
579 Cerebellar Ataxia and Coenzyme Q Deficiency through Loss of Unorthodox Kinase
580 Activity. *Mol Cell.* 2016 Aug 18;63(4):608–20.

581 49. Luna-Sanchez M, Diaz-Casado E, Barca E, Tejada MA, Montilla-Garcia A, Cobos EJ, et al.
582 The clinical heterogeneity of Coenzyme Q10 deficiency results from genotypic
583 differences in the Coq9 gene. *EMBO Mol Med.* 2015;7(5):670–87.

584 50. Ashraf S, Gee HY, Woerner S, Xie LX, Vega-Warner V, Lovric S, et al. ADCK4 mutations
585 promote steroid-resistant nephrotic syndrome through CoQ10 biosynthesis disruption.
586 *J Clin Invest.* 2013;123(12):5179–89.

587 51. Floyd BJ, Wilkerson EM, Veling MT, Minogue CE, Xia C, Beebe ET, et al. Mitochondrial
588 Protein Interaction Mapping Identifies Regulators of Respiratory Chain Function. *Mol*
589 *Cell.* 2016 Aug 18;63(4):621–32.

590 52. Yen HC, Liu YC, Kan CC, Wei HJ, Lee SH, Wei YH, et al. Disruption of the human COQ5-
591 containing protein complex is associated with diminished Coenzyme Q10 levels under
592 two different conditions of mitochondrial energy deficiency. *Biochim Biophys Acta -*
593 *Gen Subj.* 2016;1860(9):1864–76.

594 53. Turunen M, Olsson J, Dallner G. Metabolism and function of Coenzyme Q. *Biochim*
595 *Biophys Acta - Biomembr.* 2004;1660(1–2):171–99.

596 54. Bentinger M, Turunen M, Zhang X-X, Yvonne Wan Y-J, Dallner G. Involvement of
597 Retinoid X Receptor α in Coenzyme Q Metabolism. *J Mol Biol.* 2003;326(3):795–803.

598 55. Brea-Calvo G, Siendones E, Sánchez-Alcázar JA, de Cabo R, Navas P. Cell survival from
599 chemotherapy depends on NF-kappaB transcriptional up-regulation of Coenzyme Q
600 biosynthesis. *PLoS One.* 2009;4(4):e5301.

601 56. Cascajo M V, Abdelmohsen K, Heon Noh J, Fernandez-Ayala DJ, Willers IM, Brea G, et al.
602 RNA-binding proteins regulate cell respiration and coenzyme Q biosynthesis by post-
603 transcriptional regulation of COQ7. *RNA Biol.* 2016;13(7):622–34.

57. Lapointe CP, Stefely JA, Jochem A, Hutchins PD, Wilson GM, Kwiecien NW, et al. Multi-omics Reveal Specific Targets of the RNA-Binding Protein Puf3p and Its Orchestration of Mitochondrial Biogenesis. *Cell Systems*. 2018;125–135.e6.
58. Veling MT, Reidenbach AG, Freiburger EC, Kwiecien NW, Hutchins PD, Drahnak MJ, et al. Multi-omic Mitoprotease Profiling Defines a Role for Oct1p in Coenzyme Q Production. *Mol Cell*. 2017;68(5):970–977.e11.
59. Martín-Montalvo A, González-Mariscal I, Pomares-Viciano T, Padilla-López S, Ballesteros M, Vazquez-Fonseca L, et al. The phosphatase Ptc7 induces Coenzyme Q biosynthesis by activating the hydroxylase Coq7 in yeast. *J Biol Chem*. 2013;288(39):28126–37.
60. Hughes BG, Harrison PM, Hekimi S. Estimating the occurrence of primary ubiquinone deficiency by analysis of large-scale sequencing data. *Sci Rep*. 2017;7(1):17744.
61. Mitsui J, Matsukawa T, Ishiura H, Fukuda Y, Ichikawa Y, Date H, et al. Mutations in COQ2 in Familial and Sporadic Multiple-System Atrophy. *N Engl J Med*. 2013;369(3):233–44.
62. Horvath R, Czermin B, Gulati S, Demuth S, Houge G, Pyle A, et al. Adult-onset cerebellar ataxia due to mutations in CABC1/ADCK3. *J Neurol Neurosurg Psychiatry*. 2012;83(2):174–8.
63. Barca E, Musumeci O, Montagnese F, Marino S, Granata F, Nunnari D, et al. Cerebellar ataxia and severe muscle CoQ 10 deficiency in a patient with a novel mutation in ADCK3. *Clin Genet*. 2016;90(2):156–60.
64. Atmaca M, Gulhan B, Korkmaz E, Inozu M, Soylemezoglu O, Candan C, et al. Follow-up results of patients with ADCK4 mutations and the efficacy of CoQ10 treatment. *Pediatr Nephrol*. 2017;32(8):1369–75.
65. Scalais E, Chafai R, Van Coster R, Bindl L, Nuttin C, Panagiotaraki C, et al. Early myoclonic epilepsy, hypertrophic cardiomyopathy and subsequently a nephrotic syndrome in a patient with CoQ10 deficiency caused by mutations in para-hydroxybenzoate-polyprenyl transferase (COQ2). *Eur J Paediatr Neurol*. 2013;17(6):625–30.
66. Diomedi-Camassei F, Di Giandomenico S, Santorelli FM, Caridi G, Piemonte F, Montini G, et al. COQ2 nephropathy: a newly described inherited mitochondriopathy with primary renal involvement. *J Am Soc Nephrol*. 2007;18(10):2773–80.
67. Salviati L, Sacconi S, Murer L, Zacchello G, Franceschini L, Laverda AM, et al. Infantile encephalomyopathy and nephropathy with CoQ10 deficiency: A CoQ10-responsive condition. *Neurology*. 2005;65(4):606–8.
68. Quinzii C, Naini A, Salviati L, Trevisson E, Navas P, Dimauro S, et al. A mutation in para-hydroxybenzoate-polyprenyl transferase (COQ2) causes primary coenzyme Q10 deficiency. *Am J Hum Genet*. 2006;78(2):345–9.
69. Gigante M, Diella S, Santangelo L, Trevisson E, Acosta MJ, Amatruda M, et al. Further phenotypic heterogeneity of CoQ10 deficiency associated with steroid resistant nephrotic syndrome and novel COQ2 and COQ6 variants. *Clin Genet*. 2017;92(2):224–6.
70. Mollet J, Giurgea I, Schlemmer D, Dallner G, Chretien D, Delahodde A, et al. Prenyldiphosphate synthase, subunit 1 (PDSS1) and OH-benzoate polyprenyltransferase (COQ2) mutations in ubiquinone deficiency and oxidative phosphorylation disorders. *J Clin Invest*. 2007;117(3):765–72.

648 71. Sadowski CE, Lovric S, Ashraf S, Pabst WL, Gee HY, Kohl S, et al. A Single-Gene Cause in
649 29.5% of Cases of Steroid-Resistant Nephrotic Syndrome. *J Am Soc Nephrol*.
650 2015;26(6):1279–89.

651 72. Desbats MA, Vetro A, Limongelli I, Lunardi G, Casarin A, Doimo M, et al. Primary
652 coenzyme Q 10 deficiency presenting as fatal neonatal multiorgan failure. *Eur J Hum*
653 *Genet*. 2015;23(9):1254–8.

654 73. McCarthy HJ, Bierzynska A, Wherlock M, Ognjanovic M, Kerecuk L, Hegde S, et al.
655 Simultaneous sequencing of 24 genes associated with steroid-resistant nephrotic
656 syndrome. *Clin J Am Soc Nephrol*. 2013;8(4):637–48.

657 74. Jakobs BS, van den Heuvel LP, Smeets RJP, de Vries MC, Hien S, Schaible T, et al. A novel
658 mutation in COQ2 leading to fatal infantile multisystem disease. *J Neurol Sci*.
659 2013;326(1–2):24–8.

660 75. Dinwiddie DL, Smith LD, Miller NA, Atherton AM, Farrow EG, Strenk ME, et al. Diagnosis
661 of mitochondrial disorders by concomitant next-generation sequencing of the exome
662 and mitochondrial genome. *Genomics*. 2013;102(3):148–56.

663 76. Starr MC, Chang IJ, Finn LS, Sun A, Larson AA, Goebel J, et al. COQ2 nephropathy: a
664 treatable cause of nephrotic syndrome in children. *Pediatr Nephrol*. 2018;1–5.

665 77. Sondheimer N, Hewson S, Cameron JM, Somers GR, Broadbent JD, Ziosi M, et al. Novel
666 recessive mutations in COQ4 cause severe infantile cardiomyopathy and
667 encephalopathy associated with CoQ 10 deficiency. *Mol Genet Metab Reports*.
668 2017;12:23–7.

669 78. Brea-Calvo G, Haack TB, Karall D, Ohtake A, Invernizzi F, Carrozzo R, et al. COQ4
670 Mutations Cause a Broad Spectrum of Mitochondrial Disorders Associated with CoQ10
671 Deficiency. *Am J Hum Genet*. 2015;96(2):309–17.

672 79. Chung WK, Martin K, J alas C, Braddock SR, Juusola J, Monaghan KG, et al. Mutations in
673 COQ4, an essential component of coenzyme Q biosynthesis, cause lethal neonatal
674 mitochondrial encephalomyopathy. *J Med Genet*. 2015;52(9):627–35.

675 80. Helbig KL, Farwell Hagman KD, Shinde DN, Mroske C, Powis Z, Li S, et al. Diagnostic
676 exome sequencing provides a molecular diagnosis for a significant proportion of
677 patients with epilepsy. *Genet Med*. 2016;18(9):898–905.

678 81. Salvati L, Trevisson E, Rodriguez Hernandez MA, Casarin A, Pertegato V, Doimo M, et al.
679 Haploinsufficiency of COQ4 causes coenzyme Q10 deficiency. *J Med Genet*.
680 2012;49(3):187–91.

681 82. Lagier-Tourenne C, Tazir M, López LC, Quinzii CM, Assoum M, Drouot N, et al. ADCK3,
682 an ancestral kinase, is mutated in a form of recessive ataxia associated with coenzyme
683 Q10 deficiency. *Am J Hum Genet*. 2008;82(3):661–72.

684 83. Anheim M, Fleury M, Monga B, Laugel V, Chaigne D, Rodier G, et al. Epidemiological,
685 clinical, paraclinical and molecular study of a cohort of 102 patients affected with
686 autosomal recessive progressive cerebellar ataxia from Alsace, Eastern France:
687 Implications for clinical management. *Neurogenetics*. 2010;11(1):1–12.

688 84. Mignot C, Apartis E, Durr A, Marques Lourenco C, Charles P, Devos D, et al. Phenotypic
689 variability in ARCA2 and identification of a core ataxic phenotype with slow progression.
690 *Orphanet J Rare Dis*. 2013;8:173.

- 691 85. Mollet J, Delahodde A, Serre V, Chretien D, Schlemmer D, Lombes A, et al. CABC1 Gene
692 Mutations Cause Ubiquinone Deficiency with Cerebellar Ataxia and Seizures. *Am J Hum*
693 *Genet.* 2008;82(3):623–30.
- 694 86. Gerards M, van den Bosch B, Calis C, Schoonderwoerd K, van Engelen K, Tijssen M, et al.
695 Nonsense mutations in CABC1/ADCK3 cause progressive cerebellar ataxia and atrophy.
696 *Mitochondrion.* 2010;10(5):510–5.
- 697 87. Hikmat O, Tzoulis C, Knappskog PM, Johansson S, Boman H, Sztromwasser P, et al.
698 ADCK3 mutations with epilepsy, stroke-like episodes and ataxia: a POLG mimic? *Eur J*
699 *Neurol.* 2016;23(7):1188–94.
- 700 88. Terracciano A, Renaldo F, Zanni G, D’Amico A, Pastore A, Barresi S, et al. The use of
701 muscle biopsy in the diagnosis of undefined ataxia with cerebellar atrophy in children.
702 *Eur J Paediatr Neurol.* 2012;16(3):248–56.
- 703 89. Blumkin L, Leshinsky-Silver E, Zerem A, Yosovich K, Lerman-Sagie T, Lev D. Heterozygous
704 Mutations in the ADCK3 Gene in Siblings with Cerebellar Atrophy and Extreme
705 Phenotypic Variability. *JIMD Rep.* 2014;12:103–7.
- 706 90. Liu YT, Hersheson J, Plagnol V, Fawcett K, Duberley KEC, Preza E, et al. Autosomal-
707 recessive cerebellar ataxia caused by a novel ADCK3 mutation that elongates the
708 protein: Clinical, genetic and biochemical characterisation. *J Neurol Neurosurg*
709 *Psychiatry.* 2014;85(5):493–8.
- 710 91. Pronicka E, Piekutowska-Abramczuk D, Ciara E, Trubicka J, Rokicki D, Karkucinska-
711 Wieckowska A, et al. New perspective in diagnostics of mitochondrial disorders: Two
712 years’ experience with whole-exome sequencing at a national paediatric centre. *J Transl*
713 *Med.* 2016;14(1):174.
- 714 92. Malgireddy K, Thompson R, Torres-Russotto D. A novel CABC1/ADCK3 mutation in
715 adult-onset cerebellar ataxia. *Park Relat Disord.* 2016;33:151–2.
- 716 93. Jacobsen JC, Whitford W, Swan B, Taylor J, Love DR, Hil R, et al. Compound
717 Heterozygous Inheritance of Mutations in Coenzyme Q8A Results in Autosomal
718 Recessive Cerebellar Ataxia and Coenzyme Q10 Deficiency in a Female Sib-Pair. *JIMD*
719 *Rep.* 2017;1–6.
- 720 94. Malicdan MC V., Vilboux T, Ben-Zeev B, Guo J, Eliyahu A, Pode-Shakked B, et al. A novel
721 inborn error of the coenzyme Q10 biosynthesis pathway: cerebellar ataxia and static
722 encephalomyopathy due to COQ5 C-methyltransferase deficiency. *Hum Mutat.*
723 2018;39(1):69–79.
- 724 95. Ogaki K, Fujioka S, Heckman MG, Rayaprolu S, Soto-Ortolaza AI, Labbé C, et al. Analysis
725 of COQ2 gene in multiple system atrophy. *Mol Neurodegener.* 2014;9:44.
- 726 96. Vasta V, Merritt II JL, Saneto RP, Hahn SH. Next-generation sequencing for
727 mitochondrial diseases: a wide diagnostic spectrum. *Pediatr Int.* 2012;54(5):585–601.
- 728 97. López LC, Schuelke M, Quinzii CM, Kanki T, Rodenburg RJT, Naini A, et al. Leigh
729 syndrome with nephropathy and CoQ10 deficiency due to decaprenyl diphosphate
730 synthase subunit 2 (PDSS2) mutations. *Am J Hum Genet.* 2006;79(6):1125–9.
- 731 98. Rötig A, Appelkvist EL, Geromel V, Chretien D, Kadhon N, Edery P, et al. Quinone-
732 responsive multiple respiratory-chain dysfunction due to widespread coenzyme
733 Q10 deficiency. *Lancet.* 2000;356(9227):391–5.

- 734 99. Rahman S, Clarke CF, Hirano M. 176th ENMC International Workshop: Diagnosis and
735 treatment of coenzyme Q10 deficiency. *Neuromuscul Disord*. 2012;22(1):76–86.
- 736 100. Iványi B, Rácz GZ, Gál P, Brinyiczki K, Bódi I, Kalmár T, et al. Diffuse mesangial sclerosis
737 in a PDSS2 mutation-induced coenzyme Q10 deficiency. *Pediatr Nephrol*.
738 2018;33(3):439–46.
- 739 101. Freyer C, Stranneheim H, Naess K, Mourier A, Felser A, Maffezzini C, et al. Rescue of
740 primary ubiquinone deficiency due to a novel COQ7 defect using 2,4-dihydroxybenzoic
741 acid. *J Med Genet*. 2015;52(11):779–83.
- 742 102. Wang Y, Smith C, Parboosingh JS, Khan A, Innes M, Hekimi S. Pathogenicity of two
743 COQ7 mutations and responses to 2,4-dihydroxybenzoate bypass treatment. *J Cell Mol*
744 *Med*. 2017;21(10):2329–43.
- 745 103. Rahman S, Hargreaves I, Clayton P, Heales S. Neonatal presentation of coenzyme Q10
746 deficiency. *J Pediatr*. 2001;139(3):456–8.
- 747 104. Duncan AJ, Bitner-Glindzicz M, Meunier B, Costello H, Hargreaves IP, López LC, et al. A
748 nonsense mutation in COQ9 causes autosomal-recessive neonatal-onset primary
749 coenzyme Q10 deficiency: a potentially treatable form of mitochondrial disease. *Am J*
750 *Hum Genet*. 2009;84(5):558–66.
- 751 105. Danhauser K, Herebian D, Haack TB, Rodenburg RJ, Strom TM, Meitinger T, et al. Fatal
752 neonatal encephalopathy and lactic acidosis caused by a homozygous loss-of-function
753 variant in COQ9. *Eur J Hum Genet*. 2016;24(3):450–4.
- 754 106. Smith AC, Ito Y, Ahmed A, Schwartzentruber JA, Beaulieu CL, Aberg E, et al. A family
755 segregating lethal neonatal coenzyme Q 10 deficiency caused by mutations in COQ9.
756 2018;
- 757 107. Heeringa SF, Chernin G, Chaki M, Zhou W, Sloan AJ, Ji Z, et al. COQ6 mutations in
758 human patients produce nephrotic syndrome with sensorineural deafness. *J Clin Invest*.
759 2011;121(5):2013–24.
- 760 108. Cao Q, Li GM, Xu H, Shen Q, Sun L, Fang XY, et al. [Coenzyme Q(10) treatment for one
761 child with COQ6 gene mutation induced nephrotic syndrome and literature review].
762 *Zhonghua er ke za zhi = Chinese J Pediatr*. 2017;55(2):135–8.
- 763 109. Park E, Ahn YH, Kang HG, Yoo KH, Won NH, Lee KB, et al. COQ6 Mutations in Children
764 With Steroid-Resistant Focal Segmental Glomerulosclerosis and Sensorineural Hearing
765 Loss. *Am J Kidney Dis*. 2017;70(1):139–44.
- 766 110. Korkmaz E, Lipska-Zietkiewicz BS, Boyer O, Gribouval O, Fourrage C, Tabatabaei M, et al.
767 ADCK4-Associated Glomerulopathy Causes Adolescence-Onset FSGS. *J Am Soc Nephrol*.
768 2016;27(1):63–8.
- 769 111. Doimo M, Trevisson E, Airik R, Bergdoll M, Santos-Ocaña C, Hildebrandt F, et al. Effect
770 of vanillic acid on COQ6 mutants identified in patients with coenzyme Q10 deficiency.
771 *Biochim Biophys Acta - Mol Basis Dis*. 2014;1842(1):1–6.
- 772 112. Vazquez-Fonseca L, Doimo M, Calderan C, Desbats MA, Acosta MJ, Cerqua C, et al.
773 Mutations in COQ8B (ADCK4) found in patients with steroid resistant nephrotic
774 syndrome alter COQ8B function. *Hum Mutat*. 2018;39(3):406–14.
- 775 113. Zhang H, Wang F, Liu X, Zhong X, Yao Y, Xiao H. Steroid-resistant nephrotic syndrome
776 caused by co-inheritance of mutations at NPHS1 and ADCK4 genes in two Chinese

777 siblings. *Intractable Rare Dis Res.* 2017;6(4):299–303.

778 114. Lolín K, Chiodini BD, Hennaut E, Adams B, Dahan K, Ismaili K. Early-onset of ADCK4
779 glomerulopathy with renal failure: a case report. *BMC Med Genet.* 2017;18(1):28.

780 115. Feng C, Wang Q, Wang J, Liu F, Shen H, Fu H, et al. Coenzyme Q10 supplementation
781 therapy for 2 children with proteinuria renal disease and ADCK4 mutation. *Med (United
782 States).* 2017;96(47):e8880.

783 116. Park E, Kang HG, Choi YH, Lee KB, Moon KC, Jeong HJ, et al. Focal segmental
784 glomerulosclerosis and medullary nephrocalcinosis in children with ADCK4 mutations.
785 *Pediatr Nephrol.* 2017;32(9):1547–54.

786 117. Louw R, Smuts I, Wilsenach K-L, Jonck L-M, Schoonen M, van der Westhuizen FH. The
787 dilemma of diagnosing Coenzyme Q 10 deficiency in muscle. *Mol Genet Metab.*
788 2018;Accepted manuscript.

789 118. Emmanuele V, López LC, López L, Berardo A, Naini A, Tadesse S, et al. Heterogeneity of
790 coenzyme Q10 deficiency: patient study and literature review. *Arch Neurol.*
791 2012;69:978–83.

792 119. Quinzii CM, Lopez LC, Galkerson RW, Dorado B, Coku J, Naini AB, et al. Reactive oxygen
793 species, oxidative stress, and cell death correlate with level of CoQ10 deficiency. *FASEB
794 J.* 2010;24(10):3733–43.

795 120. López-Martín JM, Salviati L, Trevisson E, Montini G, DiMauro S, Quinzii C, et al. Missense
796 mutation of the COQ2 gene causes defects of bioenergetics and de novo pyrimidine
797 synthesis. *Hum Mol Genet.* 2007;16(9):1091–7.

798 121. Rodríguez-Hernández Á, Cordero MD, Salviati L, Artuch R, Pineda M, Briones P, et al.
799 Coenzyme Q deficiency triggers mitochondria degradation by mitophagy. *Autophagy.*
800 2009;5(1):19–32.

801 122. Peng M, Ostrovsky J, Kwon YJ, Polyak E, Licata J, Tsukikawa M, et al. Inhibiting cytosolic
802 translation and autophagy improves health in mitochondrial disease. *Hum Mol Genet.*
803 2015;24(17):4829–47.

804 123. Quinzii CM, Luna-Sanchez M, Ziosi M, Hidalgo-Gutierrez A, Kleiner G, Lopez LC. The Role
805 of Sulfide Oxidation Impairment in the Pathogenesis of Primary CoQ Deficiency. *Front
806 Physiol.* 2017;8:525.

807 124. Fazakerley DJ, Chaudhuri R, Yang P, Maghazal GJ, Thomas KC, Krycer JR, et al.
808 Mitochondrial CoQ deficiency is a common driver of mitochondrial oxidants and insulin
809 resistance. *Elife.* 2018;7:e32111.

810 125. Desbats MA, Morbidoni V, Silic-Benussi M, Doimo M, Ciminale V, Cassina M, et al. The
811 COQ2 genotype predicts the severity of Coenzyme Q10 deficiency. *Hum Mol Genet.*
812 2016;25(19):4256–65.

813 126. Salviati L, Trevisson E, Doimo M, Navas P. Primary Coenzyme Q10 Deficiency. Adam MP,
814 Ardinger HH, Pagon RA, Wallace SE, Bean LJH, Stephens K, et al., editors.
815 *GeneReviews®*. University of Washington, Seattle; 1993-2018; 2017.

816 127. Yubero, D.; Montero, R.; Armstrong, J.; Espinos, C.; Palau, F.; Santos-Ocaña, C.; Salviati,
817 L.; Navas, P.; Artuch R. Molecular diagnosis of coenzyme Q10 deficiency. *Expert Rev
818 Mol Diagn.* 2015;15(8):1049–59.

819 128. Rodríguez-Aguilera JC, Cortés AB, Fernández-Ayala DJM, Navas P. Biochemical

820 Assessment of Coenzyme Q10 Deficiency. *J Clin Med*. 2017;6(3):E27.

821 129. Yubero D, Allen G, Artuch R, Montero R. The Value of Coenzyme Q10 Determination in
822 Mitochondrial Patients. *J Clin Med*. 2017;6(4):37.

823 130. Artuch R, Brea-Calvo G, Briones P, Aracil A, Galván M, Espinós C, et al. Cerebellar ataxia
824 with coenzyme Q10 deficiency: diagnosis and follow-up after coenzyme Q10
825 supplementation. *J Neurol Sci*. 2006 Jul 15;246(1–2):153–8.

826 131. Yubero D, Montero R, Ramos M, Neergheen V, Navas P, Artuch R, et al. Determination
827 of urinary coenzyme Q 10 by HPLC with electrochemical detection: Reference values for
828 a paediatric population. *BioFactors*. 2015;41(6):424–30.

829 132. Bhagavan HN, Chopra RK. Coenzyme Q10: Absorption, tissue uptake, metabolism and
830 pharmacokinetics. *Free Radic Res*. 2006;40(5):445–53.

831 133. Zaki NM. Strategies for oral delivery and mitochondrial targeting of CoQ10. *Drug Deliv*.
832 2016;23(6):1868–81.

833 134. Stocker R, Bowry VW, Frei B. Ubiquinol-10 protects human low density lipoprotein
834 more efficiently against lipid peroxidation than does alpha-tocopherol. *Proc Natl Acad*
835 *Sci*. 1991;88(5):1646–50.

836 135. Mohr D, Bowry VW, Stocker R. Dietary supplementation With coenzyme Q 10 results in
837 increased levels of ubiquinol-10 within circulating lipoproteins and increased resistance
838 of human low density lipoprotein to the initiation of lipid peroxidation. *Biochim Biophys*
839 *Acta*. 1992;1126(3):247–54.

840 136. Potgieter M, Pretorius E, Pepper MS. Primary and secondary coenzyme Q10 deficiency:
841 The role of therapeutic supplementation. *Nutr Rev*. 2013;71(3):180–8.

842 137. Montini G, Malaventura C, Salviati L. Early coenzyme Q10 supplementation in primary
843 coenzyme Q10 deficiency. *N Engl J Med*. 2008 Jun 26;358(26):2849–50.

844 138. Saiki R, Lunceford AL, Shi Y, Marbois B, King R, Pachuski J, et al. Coenzyme Q₁₀
845 supplementation rescues renal disease in *Pdss2*^{kd/kd} mice with mutations in prenyl
846 diphosphate synthase subunit 2. *Am J Physiol Physiol*. 2008 Nov;295(5):F1535–44.

847 139. Herebian D, Seibt A, Smits SHJ, Bünning G, Freyer C, Prokisch H, et al. Detection of 6-
848 demethoxyubiquinone in CoQ10 deficiency disorders: Insights into enzyme interactions
849 and identification of potential therapeutics. *Mol Genet Metab*. 2017;121(3):216–23.

850 140. Wang Y, Ozer D, Hekimi S. Mitochondrial function and lifespan of mice with controlled
851 ubiquinone biosynthesis. *Nat Commun*. 2015;6:6393.

852 141. Herebian D, Seibt A, Smits SHJ, Rodenburg RJ, Mayatepek E, Distelmaier F. 4-
853 Hydroxybenzoic acid restores CoQ₁₀ biosynthesis in human COQ2 deficiency. *Ann Clin*
854 *Transl Neurol*. 2017 Dec;4(12):902–8.

855 142. Yubero D, Montero R, Martin MA, Montoya J, Ribes A, Grazina M, et al. Secondary
856 Coenzyme Q10 deficiencies in oxidative phosphorylation (OXPHOS) and non-OXPHOS
857 disorders. *Mitochondrion*. 2016;30:51–8.

858 143. Desbats MA, Lunardi G, Doimo M, Trevisson E, Salviati L. Genetic bases and clinical
859 manifestations of Coenzyme Q10 (CoQ10) deficiency. *J Inherit Metab Dis*.
860 2015;38(1):145–56.

861 144. Sacconi S, Trevisson E, Salviati L, Aymé S, Rigal O, Garcia Redondo A, et al. Coenzyme

- Q10 is frequently reduced in muscle of patients with mitochondrial myopathy. Neuromuscul Disord. 2010 Jan;20(1):44–8.
145. Montero R, Grazina M, López-Gallardo E, Montoya J, Briones P, Navarro-Sastre A, et al. Coenzyme Q10 deficiency in mitochondrial DNA depletion syndromes. Mitochondrion. 2013 Jul;13(4):337–41.
 146. Barca E, Kleiner G, Tang G, Ziosi M, Tadesse S, Masliah E, et al. Decreased Coenzyme Q10 levels in multiple system atrophy cerebellum. J Neuropathol Exp Neurol. 2016;75(7):663–72.
 147. Hernández-Camacho JD, Bernier M, López-Lluch G, Navas P. Coenzyme Q10 Supplementation in Aging and Disease. Front Physiol. 2018;9:44.
 148. Marcoff L, Thompson PD. The Role of Coenzyme Q10 in Statin-Associated Myopathy. A Systematic Review. J Am Coll Cardiol. 2007;49(23):2231–7.
 149. Uličná O, Vančová O, Waczulíková I, Božek P, Šikurová L, Bada V, et al. Liver mitochondrial respiratory function and coenzyme q content in rats on a hypercholesterolemic diet treated with atorvastatin. Physiol Res. 2012;61(2):185–93.
 150. Quinzii CM, Hirano M. Primary and secondary CoQ(10) deficiencies in humans. Biofactors. Jan;37(5):361–5.

Summary

- CoQ is an endogenously synthesized lipid that is essential for the electron transport in the mitochondrial respiratory chain.
- Primary CoQ deficiencies are rare diseases caused by mutations in genes of the CoQ biosynthesis pathway.
- CoQ deficiencies are characterized by reduced levels of CoQ affecting energy production.
- Primary CoQ deficiencies show highly heterogeneous manifestations mainly affecting CNS, PNS, sensory organs, kidney, skeletal muscle and heart.
- Currently, it is hard to establish any genotype-phenotype correlations for these diseases, partially due to the low amount of studied patients.
- It is essential to biochemically determine CoQ deficiency since supplementation has positive therapeutic effects.

Figure legends

Figure1. (A) Chemical structure of Coenzyme Q (CoQ) and (B) redox cycle of its head group. (C) Integration of CoQ reduction by different dehydrogenases in the mETC. DHODH: Dihydroorotate dehydrogenase; G3PDH: Glycerol 3 phosphate dehydrogenase; ETF-FAD: Electron Transfer Flavoprotein; ETF-Qase: Electron Transfer Flavoprotein cCoenzyme Q reductase; Cyt c: cytochrome c; SQR: sulphide-quinone oxidoreductase; PROD: proline dehydrogenase.

Figure 2. (A) Schematic model of human CoQ biosynthesis pathway. Blue arrows represent enzymatic reactions and circled numbers represent the different COQ proteins that participate in each step. Brown arrows indicate regulatory mechanisms. Circled question mark shows currently unidentified enzymes. (B) Model of human CoQ biosynthetic complex, containing at least COQ3-COQ9 and lipids, such as CoQ itself. (C) and (D) green boxes contain 4-HB analogues, defined as unnatural CoQ precursors, which are able to lead to CoQ production, bypassing defective COQ enzymes such as COQ6 (3,4-dihydroxybenzoate (3,4-dHB) or vanillic acid (VA)) or COQ7 (2,4-dihydroxybenzoate (2,4-dHB). COQ9 patient fibroblasts can also benefit from 2,4-dHB and VA. DDMQ: demethoxy-demethyl-Coenzyme Q; DMQ: demethoxy-Coenzyme Q; DMeQ: demethyl-Coenzyme Q

Figure 3. Organs and systems affected in individuals with primary CoQ deficiency, associating specific clinical manifestations with the genes involved in each one. For abbreviations go to Table 3. For frequency of each symptom linked to a specific gene go to Table 2.